Arsenal Biosciences confirmed cutting 50% of its staff as the clinical-stage cell therapy startup pivots to focus resources. Despite raising $325 million and partnerships with Bristol Myers Squibb, the company is restructuring to prioritize clinical development over early-stage research, reflecting broader challenges within the cell therapy sector. This workforce reduction signals a recalibration of strategic priorities in a competitive and capital-intensive market for innovative cell therapies.